Fabry Disease: all 246 studies
Page 3 of 3. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)CompletedNCT01730482Phase 1
- Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal FunctionCompletedNCT01730469Phase 1
- Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.Status unknownNCT01695161
- Evaluate the Safety and Exploratory Efficacy of GC1119CompletedNCT01653444Phase 1
- Pulmonary Involvement in Patients With Fabry DiseaseCompletedNCT01632111
- Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry DiseaseWithdrawnNCT01588314Phase 2
- Migalastat Food Effect StudyCompletedNCT01489995Phase 1
- Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of BiomarkersStatus unknownNCT01442350
- Fabry and Cardiomyopathy (FaCard)WithdrawnNCT01429597
- Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'AzurCompletedNCT01374997Not applicable
- Home Therapy With Replagal in Fabry DiseaseCompletedNCT01355146
- Pulmonary Disease and Exercise Tolerance in Boys With Fabry DiseaseStatus unknownNCT01304875
- Androgenetic Alopecia in Fabry DiseaseCompletedNCT01295008
- Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple SclerosisCompletedNCT01271699
- The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry DiseaseCompletedNCT01268241
- Sophisticated Assessment of Disease Burden in Patients With Fabry DiseaseCompletedNCT01210196
- Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic CardiomyopathyCompletedNCT01198899
- Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry DiseaseCompletedNCT01182818
- Prevalence of Fabry's Disease in a Population of Patients With Chronic PainsCompletedNCT01178164Not applicable
- Establishment of Biomarkers for Fabry DiseaseCompletedNCT01165697
- Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke ClinicStatus unknownNCT01109875Not applicable
- Treatment Protocol of Replagal for Patients With Fabry DiseaseNo longer availableNCT01031173
- Fabry Screening StudyCompletedNCT01019629
- Viennese Prevalence Study of Anderson-Fabry DiseaseStatus unknownNCT00871611
- Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement TherapyCompletedNCT00728364
- Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry DiseaseStatus unknownNCT00487630Phase 4
- The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) StudyCompletedNCT00446862
- Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke PatientsCompletedNCT00414583
- Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke RehabilitationCompletedNCT00413595
- An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry DiseaseCompletedNCT00357786Phase 1
- Antiproteinuric Agents and Fabry DiseaseCompletedNCT00343577
- A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.WithdrawnNCT00312767Phase 4
- A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.CompletedNCT00233870
- Neuropathic Pain and Fabry DiseaseCompletedNCT00168974
- Enzyme Replacement Therapy in Fabry DiseaseTerminatedNCT00149318
- Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A ActivityCompletedNCT00106912
- Replagal Enzyme Replacement Therapy for Adults With Fabry DiseaseCompletedNCT00097890Phase 4
- Alternative Dosing and Regimen of Replagal to Treat Fabry DiseaseCompletedNCT00075244Phase 2
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedNCT00074971Phase 3
- An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry DiseaseCompletedNCT00071877Phase 2
- Registry of Fabry Disease - A Multicenter Observational StudyCompletedNCT00055016
- Alpha-Galactosidase A Replacement Therapy for Fabry DiseaseCompletedNCT00048906Phase 2
- Data Collection in Women With Fabry DiseaseCompletedNCT00030134
- PET Scans in Normal Volunteers and Patients With Fabry DiseaseCompletedNCT00005111
- Vasodilation in Patients With Fabry's DiseaseCompletedNCT00001774
- Analysis of the Nervous System in Patients With Fabry's DiseaseCompletedNCT00001491